D espite recent advances and declining its incidence in males in Western countries, lung cancer remains the main cause of cancer deaths worldwide, mainly because of tobacco smoking epidemics in developing countries and the still moderate efficacy of therapeutic strategies [1–3]. More than 80% of lung cancers are nonsmall cell lung cancer (NSCLC), which can be further sub-divided into squamous c...

Abbreviations: CG control group; CR chest radiograph; ELCAP Early Lung Cancer Detection Project; FN false negative; FP false positive; HRCT high-resolution CT; IG intervention group; LC lung cancer; LCM lung cancer mortality; LDCT screening helical low-dose CT; MLP Mayo Lung Project; mSv millisieverts; NSCLC nonsmall cell lung cancer; SCR screening chest radiograph; TN true negative; TP true po...

In patients who undergo complete resection of a nonsmall cell lung cancer (NSCLC) post-operative followup to detect locoregional and distant recurrences is indicated in order to find potentially treatable lesions at an early stage. There is also an increased risk of developing a second primary lung cancer, unrelated to the previous tumour. Thus, secondary screening may also be worthwhile in thi...

Alectinib shows remarkable efficacy against anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC), with minimal adverse effects. Therefore, alectinib may provide a survival benefit to ALK-positive NSCLC patients with a poor performance status. If the medication cannot be taken by mouth, the patient may be given alectinib through a nasogastric tube.

The role of p53, as a prognostic factor for survival in lung cancer, is controversial and the purpose of the present systematic review of the literature is to determine this effect. Published studies were identified with the objective to aggregate the available survival results after a methodological assessment using a scale specifically designed by the European Lung Cancer Working Party (ELCWP...

The present study aimed to determine the alterations of antioxidant activities in erythrocytes from patients with nonsmall cell lung carcinoma (NSCLC). A comparative study of the systemic antioxidant activities in red blood cell lysate from subjects with NSCLC and healthy control subjects was conducted. The antioxidants catalase, superoxide dismutase (SOD) and glutathione peroxidase (GPx) were ...

Objective: Lung cancer is a leading cause of cancer-related death worldwide. Most lung cancers are nonsmall cell lung cancer (NSCLC). The overall survival of NSCLC patients with advanced stage or metastatic lesions remains very poor. Therefore, the development of novel treatments for NCSLC is clinically needed. Previous studies reported a relationship between calpain, a calcium-dependent intrac...

The quality-of-life and overall survival are improved by platinum-based chemotherapy in patients with localized or disseminated small-cell lung cancer (SCLC) [1, 2]. In nonsmall-cell lung cancer (NSCLC), platinum-based combinations with new agents (vinorelbine, gemcitabine, taxanes) improve survival in both resected and advanced NSCLC patients [3–6]. Nevertheless, a therapeutic plateau has been...

background: lung carcinoma is a multiple type cancer comprising of small cell and non-small cell carcinomas (nsclc). for therapeutic and diagnostic purposes, serum monoclonal antibodies have been produced against lung cancer. objective: to charac-terize a murine monoclonal antibody (me3d11) reactive with human nsclc. methods: a murine monoclonal antibody (me3d11) reactive with human nsclc was s...

Approximately two thirds of all patients with newly diagnosed non-small cell lung cancer (NSCLC) have advanced disease (stage IIIB or IV) that is only amenable to palliative chemotherapy. In this setting chemotherapy has a proven efficacy and platinum-based doublet regimens are the mainstay of front-line therapy (Nonsmall Cell Lung Cancer Collaborative Group, 1995; Pfisher et al., 2004). Vinore...